Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study.
Humans
Stomach Neoplasms
/ drug therapy
Ramucirumab
Male
Female
Thymine
Middle Aged
Aged
Trifluridine
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Pyrrolidines
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Retrospective Studies
Adult
Drug Combinations
Aged, 80 and over
Treatment Outcome
Uracil
/ analogs & derivatives
Progression-Free Survival
Chemotherapy
Gastric cancer
Ramucirumab
Trifluridine/tipiracil
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 Jun 2024
03 Jun 2024
Historique:
received:
05
01
2024
accepted:
13
05
2024
medline:
4
6
2024
pubmed:
4
6
2024
entrez:
3
6
2024
Statut:
epublish
Résumé
The combination of trifluridine/tipiracil hydrochloride (FTD/TPI) plus ramucirumab has demonstrated clinical activity in patients with advanced gastric cancer (AGC). We evaluated the efficacy and safety of this combination compared with those of FTD/TPI monotherapy in patients with AGC. We retrospectively reviewed data of patients with AGC who received FTD/TPI plus ramucirumab or FTD/TPI monotherapy as third- or later-line treatment. This study included 36 patients treated with FTD/TPI plus ramucirumab and 70 patients receiving FTD/TPI monotherapy. The objective response rate (ORR) and disease control rate (DCR) were 25.8% and 58.1%, respectively, in the FTD/TPI plus ramucirumab group and 5.0% and 38.3%, respectively, in the FTD/TPI group (ORR, P = 0.007; DCR, P = 0.081). The median progression-free survival (PFS) was significantly longer in the FTD/TPI plus ramucirumab group (median PFS, 2.9 vs. 1.8 months; hazard ratio [HR]: 0.52; P = 0.001). A numerical survival benefit was also observed (median overall survival, 7.9 months vs. 5.0 months; HR: 0.68, P = 0.089). In the multivariate analysis, PFS was significantly longer in the FTD/TPI plus ramucirumab group than in the FTD/TPI monotherapy group (HR: 0.61, P = 0.030). The incidence of febrile neutropenia was higher in the FTD/TPI plus ramucirumab group than in the FTD/TPI group (13.8% vs. 2.9%); however, no new safety signals were identified. Compared with FTD/TPI monotherapy, FTD/TPI plus ramucirumab offers clinical benefits with acceptable toxicity in heavily pretreated patients with AGC. Further investigation via randomized trials is warranted to confirm these findings.
Identifiants
pubmed: 38830895
doi: 10.1038/s41598-024-61975-7
pii: 10.1038/s41598-024-61975-7
doi:
Substances chimiques
Ramucirumab
D99YVK4L0X
Thymine
QR26YLT7LT
Trifluridine
RMW9V5RW38
Antibodies, Monoclonal, Humanized
0
Pyrrolidines
0
Drug Combinations
0
trifluridine tipiracil drug combination
0
Uracil
56HH86ZVCT
Types de publication
Journal Article
Observational Study
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
12658Informations de copyright
© 2024. The Author(s).
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
doi: 10.3322/caac.21660
pubmed: 33538338
Murad, A. M. et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 72(1), 37–41 (1993).
doi: 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P
pubmed: 8508427
Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer 26(1), 1–25 (2023).
Komatsu, Y. et al. Treatment pattern for advanced gastric cancer in Japan and factors associated with sequential treatment: A retrospective administrative claims database study. Adv. Ther. 39(1), 296–313 (2022).
doi: 10.1007/s12325-021-01931-3
pubmed: 34716560
Shitara, K. et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19(11), 1437–1448 (2018).
doi: 10.1016/S1470-2045(18)30739-3
pubmed: 30355453
Tsukihara, H. et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol. Rep. 33(5), 2135–2142 (2015).
pubmed: 25812794
pmcid: 4391594
Prager, G. W. et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N. Engl. J. Med. 388(18), 1657–1667 (2023).
doi: 10.1056/NEJMoa2214963
pubmed: 37133585
Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol. 15(11), 1224–1235 (2014).
doi: 10.1016/S1470-2045(14)70420-6
pubmed: 25240821
Fuchs, C. S. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 383(9911), 31–39 (2014).
doi: 10.1016/S0140-6736(13)61719-5
pubmed: 24094768
Kawazoe, A. et al. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: An open-label, single-arm, phase 2 trial. Lancet Gastroenterol. Hepatol. 6(3), 209–217 (2021).
doi: 10.1016/S2468-1253(20)30396-4
pubmed: 33508242
Goetze, T. O. et al. Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy. Int. J. Cancer 153(10), 1726–1733 (2023).
doi: 10.1002/ijc.34652
pubmed: 37455496
Narita, Y. et al. Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): A prospective observational study. ESMO Open. 8(6), 102071 (2023).
doi: 10.1016/j.esmoop.2023.102071
pubmed: 38016249
pmcid: 10774960
Nakajima, T. E. et al. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. Clin. Cancer Res. 27(4), 1029–1036 (2021).
doi: 10.1158/1078-0432.CCR-20-3559
pubmed: 33262133
Kato, K. et al. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer 22(2), 344–354 (2019).
doi: 10.1007/s10120-018-0899-6
pubmed: 30506519
Thuss-Patience, P. C. et al. Ramucirumab, avelumab, and paclitaxel (RAP) as second-line treatment in gastro-esophageal adenocarcinoma, a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J. Clin. Oncol. 40(16_suppl), 4051 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.4051
Fukuoka, S. et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: An open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J. Clin. Oncol. 38(18), 2053–2061 (2020).
doi: 10.1200/JCO.19.03296
pubmed: 32343640
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer. 45(2), 228–247 (2009).
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
National Cancer Institute Common Toxicity Criteria version 5.0. https://evs.nci.nih.gov/ftp1/CTCAE/About.html .
Masi, G. et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial. Ann. Oncol. 26(4), 724–730 (2015).
doi: 10.1093/annonc/mdv012
pubmed: 25600568
Akamatsu, H. et al. Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune checkpoint inhibitors and had ICI-free intervals (WJOG9616L). Clin. Cancer Res. 28(15), Of1–Of7 (2022).
doi: 10.1158/1078-0432.CCR-22-0602
pubmed: 35762926
Okunaka, M. et al. Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience. Gastric Cancer 26(6), 1030–1039 (2023).
doi: 10.1007/s10120-023-01427-9
pubmed: 37665515
Kadowaki, S. et al. LBA76 The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial). Ann. Oncol. 34, S1317–S1318 (2023).
doi: 10.1016/j.annonc.2023.10.077
Takahashi, N. et al. Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G). BMC Cancer. 23(1), 726 (2023).
doi: 10.1186/s12885-023-11199-1
pubmed: 37543568
pmcid: 10403909
Williamson, T., Sultanpuram, N. & Sendi, H. The role of liver microenvironment in hepatic metastasis. Clin. Transl. Med. 8(1), 21 (2019).
doi: 10.1186/s40169-019-0237-6
pubmed: 31263976
pmcid: 6603103
Ogata, T. et al. 1418P Chronological improvement in the survival of advanced gastric cancer patients in the past 15 years. Ann. Oncol. 32, S1064 (2021).
doi: 10.1016/j.annonc.2021.08.1527
Xu, R.-H. et al. RAINBOW-Asia: A randomized, multicenter, double-blind, phase III study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line chemotherapy with platinum and fluoropyrimidine. J. Clin. Oncol. 39(3_suppl), 199 (2021).
doi: 10.1200/JCO.2021.39.3_suppl.199
Yang, Y. et al. Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism. Nat. Commun. 7, 12680 (2016).
doi: 10.1038/ncomms12680
pubmed: 27580750
pmcid: 5025794
Conway, J. W. et al. VEGF inhibitors improve survival outcomes in patients with liver metastases across cancer types—A meta-analysis. Cancers. 15(20), 5012 (2023).
doi: 10.3390/cancers15205012
pubmed: 37894379
pmcid: 10605052
Kato, K. et al. Efficacy of cytotoxic agents after progression on anti-PD-(L)1 antibody for pre-treated metastatic gastric cancer. Anticancer Res. 40(4), 2247–2255 (2020).
doi: 10.21873/anticanres.14187
pubmed: 32234921
Osa, A. et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 3(19), e59125 (2018).
doi: 10.1172/jci.insight.59125
pubmed: 30282824
pmcid: 6237460
Yoshino, T. et al. Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: Results of a systematic review and meta-analysis. Ther. Adv. Med. Oncol. 15, 17588359221146136 (2023).
doi: 10.1177/17588359221146137
pubmed: 36743525
pmcid: 9893398
Yoshino, T. et al. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Ann. Oncol. 31(1), 88–95 (2020).
doi: 10.1016/j.annonc.2019.10.005
pubmed: 31912801
Hamauchi, S. et al. Neutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102. Clin. Colorectal Cancer. 16(1), 51–57 (2017).
doi: 10.1016/j.clcc.2016.07.005
pubmed: 27522626